Ambit's powerful profiling technology, innovative licensing strategy, history of kinase expertise and pipeline of cancer therapeutics are making news.
12.09.08Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia
04.23.08High Throughput Kinase Screening Expedites Drug Discovery and Development